Our own experience now for 3 years, no conflict of interests

The authors conclude that a commercial preparation of Echinacea (Echinaforce) was a safe, easy-to-use, and cost-efficient intervention with antiviral activities that positively effecting RTI and SARS-CoV-2 by reducing virus loads. The authors suggest that EF supplementation is beneficial as an adjunctive measure in addition to vaccinations, social distancing, and wearing protective facemasks. Further studies are needed to confirm the results observed.

Two authors are employed by Convex Ltd and one by Medistat Services Ltd. Six authors have received honorariums from the study sponsor which was A. Vogel, the maker of the supplement used in the study. All other authors report no conflict of interest.

—Samaara Robbins Published by the American Botanical council